xt-150
Gene therapyexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 21, 2018 (NCT03282149)
Timeline
Indications
Mechanism of action
- Interleukin-10Supplementation
IL10 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06704347 | Phase 1 | Feb 28, 2025 | Xalud Therapeutics, Inc. |
| NCT05196919 | Phase 2 | Feb 24, 2022 | Xalud Therapeutics, Inc. |
| NCT04841512 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2022 | Xalud Therapeutics, Inc. |
| NCT04466410 | Phase 1 | Oct 15, 2020 | Xalud Therapeutics, Inc. |
| NCT04124042 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2020 | Xalud Therapeutics, Inc. |
| NCT03769662 | Phase 1 | Mar 20, 2019 | University of Adelaide, Xalud Therapeutics, Inc. |
| NCT03477487 | Phase 1 | Jun 8, 2018 | Xalud Therapeutics, Inc. |
| NCT03282149 | Phase 1 | Mar 21, 2018 | University of Adelaide, Xalud Therapeutics, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xalud Therapeutics, Inc. | For profit | 8 | 8 | 3 | 2018 |
| University of Adelaide | Academic/Hospital | 2 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1